Trial Profile
Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2021
Price :
$35
*
At a glance
- Drugs SNS 301 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Sensei Biotherapeutics
- 03 Apr 2019 Long-term immunogenicity results, presented at the 110th Annual Meeting of the American Association for Cancer Research
- 01 Apr 2019 According to a Sensei Biotherapeutics media release, data from this trial were presented at the American Association for Cancer Research (AACR) Annual Meeting 2019.
- 28 Feb 2019 According to a Sensei Biotherapeutics media release, data on long-term effects of SNS-301 will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia March 29 - April 3, 2019.